CMS Entry id: 2709 | Channel: Blog landing page | Template: blog/index

Login
Facebook YouTube Twitter Linkedin
Facebook YouTube Twitter Linkedin

Blog

Three ways you can design better drug trials for schizophrenia therapeutics

To date, no effective drugs have been developed to address cognitive dysfunction in schizophrenia. Here we will highlight the three main methodological challenges which may be contributing to these high failure rates, and propose potential practical solutions to these problems.                                                                                                                                                                                                  

Exploring participant-level trajectories of cognitive performance in patients with schizophrenia

Cambridge Cognition and Boehringer Ingelheim have been investigating cognitive performance among patients with schizophrenia, with a view to improving future pro-cognitive drug trial designs. Our Director of Neuroscience, Dr Kiri Granger, presented the latest findings at ISCTM and SIRS.

Can acetylcholinesterase inhibitors and CNS stimulants tackle cognitive dysfunction in multiple scle

Cognitive dysfunction in multiple sclerosis (MS) presents a significant, unmet therapeutic need. Researchers at Cambridge Cognition and the University of Manchester investigated potential solutions to this problem with a systematic review and meta-analysis of pro-cognitive drug trials in MS. 

Patient recruitment: are you selecting the right patients for schizophrenia clinical trials?

The importance of recruiting patients for pro-cognitive drug trials in schizophrenia on the basis of cognitive dysfunction. 

Improving clinical trials for pro-cognitive drugs in schizophrenia

Introducing a blog-post series to discuss key limitations, and potential improvements, for pro-cognitive drug trials in schizophrenia.

The benefits of language and culture independent touchscreen cognitive tests

When assessing cognitive function, tests that are reliable, time and cost efficient and are comparable across cultures and languages are the key to producing accurate and valid results. There are various cognitive assessment tools out there, but what are the benefits of using language and culture independent touchscreen tests such as CANTAB?

web-based testing, wearables, voice recognition, virtual research, virtual clinical trials, technology, swm, subjective measures, stigma, social cognition, soc, smartphones, schizophrenia research, schizophrenia, research funding, remote testing, regulations, recruitment, real-world assessments, prodromal, pro-cognitive, presenteeism, preclinical, precision psychiatry, pre-clinical, physical health, personalised medicine, patient-centric, patient recruitment, patient finding, parkinson's disease, pal, ots, opinion piece, occupational health, objective measures, normative data, neurotech, neuroscience, near-patient testing, multiple sclerosis, ms, modelling, modafinil, mental wellbeing, mental health, mci, major depression, lifespan, innovate uk, ied, icosr, high frequency, healthcare, ert, epidemiology, emotion recognition, ecological momentary assessments, ebt, ebbinghaus, early alzheimer's disease, drug development, digital tools, digital health, diagnosis, depression, dementia, computerised testing, cognitive testing, cognitive science, cognitive safety, cognitive impairment, cognitive function, cognitive dysfunction, cognitive deficits, cognitive biomarkers, cognitive assessment, cognition kit, cognition, cns summit, clinical trials, clinical trial, cias, chronic pain, cgt, cantab research grant, cantab for clinical trials, cantab, brain health, brain donor program, biomarkers, awards, automatic speech recognition, autism, attention, at-home testing, asd, alzheimer's disease, affective cognition, absenteeism,